BioAegis co-founder, Steve Cordovano, was invited to present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City. The presentation, “Conquering Disease Driven by Excess Inflammation” will highlight BioAegis’ novel, host-directed immune regulator protein. The presentation will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (ARDS), and its phase 2 global clinical study. 

The presentation will take place on Thursday, September 19th at 10:25 am and can be watched live by registering at this link.